Form 4: Turning Point Brands Executive Chairman David Glazek Reports Stock and Option Grants
SEC Form 4 Filing
David Glazek, Executive Chairman of Turning Point Brands, reports the acquisition of common stock and options under the company's equity incentive plan.
Summary
- On March 11, 2024, David Glazek, Executive Chairman of Turning Point Brands, reported transactions involving the company's securities.
- Glazek acquired 18,389 shares of common stock at a price of $27.19 per share.
- He also acquired 54,289 options with an exercise price of $27.19, expiring on March 11, 2034.
- These options vest in 25% increments on the last day of each calendar quarter of 2024.
- Additionally, Glazek holds 77,519 options with an exercise price of $20.71, expiring on May 12, 2033, which vest in 25% increments on the last day of each calendar quarter of 2023.
- Following these transactions, Glazek beneficially owns 105,193 shares of common stock, including 50,623 restricted stock units (RSUs) and 54,570 shares of common stock, as well as 54,289 options granted in 2024 and 77,519 options granted in 2023.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock and option grants to an executive, which is neither overwhelmingly positive nor negative. It reflects standard compensation practices.
Positives
- The grant of options and restricted stock units aligns the Executive Chairman's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the Executive Chairman.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Comparison to Industry Standards
- Equity grants to executive management are a common practice across publicly traded companies to incentivize performance and align interests with shareholders.
- The vesting schedules and option terms are generally consistent with industry norms for executive compensation packages.
Stakeholder Impact
- The stock and option grants may have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 05/12/2023 | Date of grant for 77,519 options with an exercise price of $20.71, expiring on 05/12/2033. |
| 03/11/2024 | Date of transaction: Acquisition of 18,389 shares of common stock and grant of 54,289 options. |
| 03/13/2024 | Date of signature for the Form 4 filing. |
| 03/11/2034 | Expiration date for 54,289 options with an exercise price of $27.19. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.